US Stock Market Movement: Genmab Surges on October 5 Due to AbbVie Collaboration, EPKINLY Phase III Results, and Rina-S

Genmab Surges on October 5th: Analysis

Keywords: AbbVie collaboration, EPKINLY Phase III, Rina-S

1. On October 6th, Genmab and AbbVie announced that the Phase III trial of EPKINLY combined with R-CHOP for the treatment of newly diagnosed diffuse large B-cell lymphoma showed a statistically significant improvement in progression-free survival, with a 51% reduction in the risk of disease progression or death.

2. On October 3rd, Genmab released data from the RAINFOL-01 trial of Rina-S for the treatment of platinum-resistant ovarian cancer: among 109 patients, the confirmed objective response rate was 45.9%, including 5 complete responses, with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. Antitumor activity was observed regardless of FRα expression level and prior treatment with mirvetuximab.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)